Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Inhibikase Therapeutics (IKT) EBITDA Margin (2020 - 2023)

Historic EBITDA Margin for Inhibikase Therapeutics (IKT) over the last 4 years, with Q4 2023 value amounting to 440356600.0%.

  • Inhibikase Therapeutics' EBITDA Margin fell 4403497803600.0% to 440356600.0% in Q4 2023 from the same period last year, while for Sep 2024 it was 2006393700.0%, marking a year-over-year decrease of 20063876552300.0%. This contributed to the annual value of 7711.98% for FY2023, which is 69741900.0% up from last year.
  • Latest data reveals that Inhibikase Therapeutics reported EBITDA Margin of 440356600.0% as of Q4 2023, which was down 4403497803600.0% from 5773.14% recorded in Q3 2023.
  • Inhibikase Therapeutics' 5-year EBITDA Margin high stood at 186.56% for Q1 2021, and its period low was 440356600.0% during Q4 2023.
  • Over the past 4 years, Inhibikase Therapeutics' median EBITDA Margin value was 5440.26% (recorded in 2023), while the average stood at 27549232.05%.
  • Per our database at Business Quant, Inhibikase Therapeutics' EBITDA Margin soared by 2000000000bps in 2022 and then plummeted by 2000000000bps in 2023.
  • Quarter analysis of 4 years shows Inhibikase Therapeutics' EBITDA Margin stood at 704.66% in 2020, then crashed by -36703bps to 259334.41% in 2021, then soared by 97bps to 6819.64% in 2022, then tumbled by -6457080bps to 440356600.0% in 2023.
  • Its last three reported values are 440356600.0% in Q4 2023, 5773.14% for Q3 2023, and 5107.38% during Q2 2023.